Bird flu vaccine protects children
NEW YORK (Reuters Health) - A vaccine to protect against infection with the bird flu virus, the pathogen experts fear is capable of causing pandemic disease in humans, proved safe and effective in a preliminary clinical trial with children, mirroring the results of a recent trial conducted in adults, Hungarian researchers report in the Pediatric Infectious Disease Journal.
Fluval (also called avian influenza A (H5N1) vaccine) was developed and produced by Omninvest LTD (Hungary), report Dr. Zoltan Vajo, of the National Center for Immunology and Allergy in Budapest, and co-authors.
Twelve healthy children, 9 to 17 years of age, received a single dose of Fluval by intramuscular injection. No side effects were detected.
On day 21, the rate of protection was 75 percent. Similar results using the same vaccine were reported last year following a clinical trial involving 146 adults.
This vaccine fulfilled all U.S. and European criteria required for licensure, the authors note.
Vajo’s team also points out that Fluval requires only one dose, while other H5N1 vaccines approved by regulatory agencies require more doses, with at least two injections administered 21 to 28 days apart.
SOURCE: Pediatric Infectious Disease Journal, December 2008.
--------------------------------------------------------------------------------------------Related Posts:
By Will Boggs, MD NEW YORK (Reuters Health) - Protection against hepatitis B appears to drop off in adolescents who got the hepatitis B vaccine beginning at birth, according to a new report. Dr. Stephanie R. Bialek from the US Centers for Disease Control and Prevention, Atlanta, Georgia, and colleagues evaluated the occurrence of breakthrough infections and
Full Post: Hepatitis B vaccine protection may wane in teens
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - A combination vaccine against diphtheria, tetanus, pertussis, polio and flu, which is routinely used in Canadian children, has been shown to be effective and well tolerated in a U.S. study. The randomized trial was conducted to support U.S. licensure of the vaccine known as DTaP5-IPV-Hib, which incorporates diphtheria-tetanus-5-component acellular pertussis (DTaP5),
Full Post: Combination vaccine safe and effective for infants
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Hepatitis A infections, usually transmitted via contaminated food, can cause debilitating illness, but protection afforded by the hepatitis A vaccine last more than a decade, a new study shows. In fact, antibodies against hepatitis A virus persist for up to 27 years after vaccination, report investigators from the Centers for Disease
Full Post: Hepatitis A vaccine gives long-lasting protection
--------------------------------------------------------------------------------------------
By Will Dunham WASHINGTON (Reuters) - A half dose of flu vaccine may work just as well as the full dose for healthy adults under 50 — a finding that could help stretch supplies in the event of a future vaccine shortage, researchers said on Monday. The study involved about 1,100 U.S. adults, about half of whom
Full Post: Flu shot half dose just as good for younger adults
--------------------------------------------------------------------------------------------
By Andrew Quinn KILIFI, Kenya (Reuters) - For a footsoldier on the cutting-edge of a global public health experiment, Michael Kenyali was looking a little wobbly. The bright eyed two-year-old, stumbling toward his mother and wailing to be fed, is part of an army of babies enlisted to test a new vaccine researchers hope will help drive
Full Post: Babies are Africa’s malaria warriors